Skip to content

Study of tolerability, biodistribution and dosimetry of Technetium-99m radiolabelled Fucoidan

Study of tolerability, biodistribution and dosimetry of Technetium-99m radiolabelled Fucoidan

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON24363
Enrollment
10
Registered
2017-11-28
Start date
2018-01-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fucoidan

Interventions

99mTc-Fucoidan SPECT/CT

Sponsors

Academic Medical Center Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Adult subjects of either gender, aged 18 years or older - BMI between 18 and 35 kg/m2 - Effective contraception in women of childbearing age - Use of effective contraception in men for 24 hours after injection of 99mTc-Fucoidan

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Progressive and chronic disease - Chronic infection with HIV, HBV or HCV - Clinically significant abnormalities during screening - Pregnancy or breast-feeding - Active medication use or previous long-term intake of medication - Any other treatment that could interfere with the conduct or interpretation of the study in the opinion of the investigator - Any other clinically relevant condition that could interfere with the conduct of the study in the opinion of the investigator - Standard contra-indications to SPECT/CT - Inability or unwilling to comply with protocol requirements, or deemed by the investigator to have a disorder that may compromise the ability to give informed

Design outcomes

Primary

MeasureTime frame
Tolerability will be evaluated on the frequency and severity of adverse events, as well as on the following parameters: -Vital signs -Physical examination -ECG -Clinical blood laboratory measurements

Secondary

MeasureTime frame
- Biodistribution (blood clearance and tissue biodistribution) - Dosimetry (effective dose in mSv per organ and per individual determined from biodistribution)

Contacts

Public ContactK.H. Zheng

Department of Vascular Medicine - Academic Medical Center

k.h.zheng@amc.nl+31 20 5667516

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)